High-level expression of protein tyrosine phosphatase non-receptor 12 is a strong and independent predictor of poor prognosis in prostate cancer

Table 2 PTPN12 staining results of the primary tumor and prostate cancer phenotype in all cancers

Parameter	N	PTPN12 (%)				P
Parameter	N	Negative	Weak	Moderate	Strong	P
All cancers	10,317	28.9	26.5	39.9	4.7
Tumor stage						< 0.0001
pT2	6438	32.8	26.9	36.7	3.6
pT3a	2385	24.2	25.7	44.6	5.5
pT3b-pT4	1448	19.5	26.0	47.0	7.6
Gleason grade						< 0.0001
≤ 3 + 3	1999	39.6	29.1	26.5	4.8
3 + 4	5526	29.2	26.9	40.3	3.6
3 + 4 Tert.5	444	26.4	26.1	44.4	3.2
4 + 3	1030	20.8	26.0	47.0	6.2
3 + 4 Tert.5	711	18.1	20.1	53.9	7.9
≥ 4 + 4	599	18.9	23.9	48.7	8.5
Quantitative Gleason grade						< 0.0001
≤ 3 + 3	1971	39.7	29.1	26.3	4.8
3 + 4 ≤ 5%	1305	33.4	27.2	36.2	3.2
3 + 4 6–10%	1288	31.4	26.8	38.5	3.3
3 + 4 11–20%	1059	28.0	25.1	44.2	2.6
3 + 4 21–30%	600	25.0	26.7	42.7	5.7
3 + 4 31–49%	483	26.5	25.5	43.9	4.1
3 + 4 Tert.5	323	28.2	28.2	41.8	1.9
4 + 3 50–60%	400	22.0	23.5	49.0	5.5
4 + 3 61–80%	345	20.0	25.2	51.0	3.8
4 + 3 > 80%	93	19.4	25.8	43.0	11.8
4 + 3 Tert.5	518	20.5	21.6	53.3	4.6
≥ 4 + 4	406	20.4	25.6	48.3	5.7
Lymph node metastasis						< 0.0001
N0	6081	27.0	26.4	41.9	4.8
N+	718	17.4	22.0	53.5	7.1
Preoperative PSA level (ng/ml)						0.0158
< 4	1222	25.1	26.1	42.7	6.1
4–10	6084	29.4	26.8	39.6	4.2
10–20	2146	29.7	25.4	39.7	5.1
> 20	752	27.9	28.1	39.5	4.5
Surgical margin						< 0.0001
Negative	8120	30.0	26.5	39.3	4.2
Positive	1982	24.3	27.0	42.2	6.4

ISSN: 1471-2407